Stock fact sheet · data as of
Elite Pharmaceuticals, Inc. (ELTP): fair value, margin of safety and Wheel Score
Ticker symbol ELTP · Healthcare · Drug Manufacturers - Specialty & Generic · United States · Blend
Is ELTP undervalued?
At 0.2400 (close of 5 Nov 2026), ELTP trades 96% below the GLS average fair value of 6.18. That average comes from 8 models run on the latest filings, and 8 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Elite Pharmaceuticals, Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
There is a wide gap between Graham Number (0.3394) and DCF (39.86). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
Ranked against every other company we cover, neither cheapness nor growth clearly wins for ELTP, so the nightly engine files it under Blend (value score 75, growth score 90, out of 100).
Nine valuation models for ELTP
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 39.86 | +16508% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 0.3394 | +41% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 3.01 | +1154% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 1.32 | +448% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 3.22 | +1242% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 0.4903 | +104% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 0.6442 | +168% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 0.5845 | +144% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.0675 | -72% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Elite Pharmaceuticals, Inc. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the "Piotroski 6 or more" Wheel Trade Filter. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. On durability ELTP scores 6.0/10 on the GLS Moat - a middle reading; the Moat Score tab on the Quote page's Financials view shows which of the four parts hold it back.
Returns on capital are high - ROIC 42.9%, ROE 45.4%, ROA 32.4% - with debt at 0.06 times equity and a free-cash-flow yield of 6.8%.
Elite Pharmaceuticals, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Licensing 100% (quarter Q1 FY2027).
Institutional ownership scores 3/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | 42.9% |
|---|---|---|---|
| GLS Moat | 6.0 / 10 | ROE | 45.4% |
| Debt / equity | 0.06 | ROA | 32.4% |
| Free-cash-flow yield | 6.8% | Payout ratio | 0% |
| Institutions | 3 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 33: No options
No options are listed on Elite Pharmaceuticals, Inc. in our nightly snapshot, so it fails the first Wheel Trade Filter (options that actually trade) (it reads 33, under 70) and is left out of every options scan; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 112k shares a day on a market cap of $259M, with a beta of 0.41 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | no listed options |
| 2 | A real business, not a gamble | Passes | Profitable over the last twelve months - not a speculative stock, fund or note |
| 3 | Below fair value | Passes | Trading below the nine-model average fair value (margin of safety above 0) |
| 4 | Financially healthy | Fails | Piotroski 5/9 (under 6) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | no implied volatility |
| 8 | Big enough | Fails | market cap $259M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 0.24 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Strong | 96% below fair value | |
| Premium | Weak | no option data | |
| Moat | Good | moat 6.0/10 | |
| Health | Fair | Piotroski 5/9 | |
| Red Flags | Fair | not scored yet - half marks | |
| Option trading | Weak | no option volume data | |
| Stability | Fair | beta 0.41, $259M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
Elite Pharmaceuticals, Inc. reports earnings on 12 Nov 2026 - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Elite Pharmaceuticals, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| LFCR Lifecore Biomedical, Inc. | 6.44 | 0.9450 | -581% | 10Weak | $244M |
| GLAS Glass House Brands Inc | 2.58 | 54.75 | +95% | 30Weak | $227M |
| SIGA SIGA Technologies, Inc. | 3.15 | 8.74 | +64% | 35Weak | $226M |
| EBS Emergent BioSolutions Inc. | 5.90 | 45.07 | +87% | 36Weak | $303M |
| CGC Canopy Growth Corporation | 0.7517 | - | - | 11Weak | $318M |
| TLRY Tilray Brands, Inc. | 2.96 | - | - | 24Weak | $331M |
| ACB Aurora Cannabis Inc. | 5.24 | - | - | 27Weak | $332M |
| NIKA Nika Pharmaceuticals Inc. | 0.3500 | 0.0000 | -19409229% | 11No options | $367M |
| VRNO Verano Holdings Corp | 5.16 | 27.65 | +81% | 30No options | $376M |
| KMDA Kamada Ltd. | 7.42 | 14.28 | +48% | 33Weak | $428M |
| TKNO Alpha Teknova, Inc. | 7.37 | - | - | 20Weak | $455M |
| AQST Aquestive Therapeutics, Inc. | 3.80 | - | - | 25Weak | $477M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ELTP
Is ELTP undervalued right now?
By the GLS models, yes: at 0.2400 the stock is 96% below the average fair value of 6.18 (data as of 5 Nov 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of ELTP and what does it mean?
ELTP has no listed options in our nightly snapshot, so it cannot be wheeled; it fails the first Wheel Trade Filter (options that actually trade), stays under 70 and is shown as "No options".
What is the GLS fair value for ELTP?
6.18 per share as of 5 Nov 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Elite Pharmaceuticals, Inc. report earnings next?
The next earnings report is due on 12 Nov 2026, 7 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does ELTP have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on ELTP, so the wheel strategy cannot be run on it and the Wheel Score stays under 70.